Summary

In this video from the 2017 Canadian Lung Cancer Conference (CLCCO), International guest speaker, Prof. Solange Peters, a well-renowned world leader in lung cancer, shares the stage with Dr. Sunil Verma, a leader in implementing I-O in the Canadian clinical setting, to present the latest trends on I-O in NSCLC. Patient advocacy group, Lung Cancer Canada, will also provide invaluable patient perspectives.


Learning Objectives

At the end of this presentation, participants will be able to:

1. Review recent advances of immune checkpoint inhibitors for advanced NSCLC.
2. Evaluate the impact of I-O therapy accounted by a real-life lung cancer patient.
3. Share European and Canadian clinical experience using I-O in NSCLC, including appropriate patient selection and management of immune-related adverse events.
4. Discuss current challenges and the future role of these novel therapies in the clinical setting.


Faculty

Prof. Solange Peters, MD-PhD
Department of Oncology, Lausanne University, Switzerland

Dr. Sunil Verma, MD, MSEd, FRCPC
Department of Oncology, University of Calgary, Alberta

Christina Sit, MSc
Program Manager, Lung Cancer Canada, Toronto, Ontario


Viewing Information

This video is available as an accredited program (Section 1, 1 hour CME credit). To access the content, please click below and you will be re-directed to our CME portal. 

*Please note that specific criteria must be fulfilled before a certificate of completion is provided. Please see below:

1. Complete the pre-test questionnaire
2. View the entire video
3. Complete the post-test questionnaire.
4. Complete the program evaluation form.

Accreditation statement:
This program meets the accreditation criteria as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of
Canada and has been accredited by the Office of Continuing Professional Development, Faculty of Medicine, McGill University for up to 1 Section 1 credits.
Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert
Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found
at www.ama-assn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity.

This program is accredited untli March 1, 2018


This program is supported by an education support from Bristol-Myers Squibb Canada


If you have any questions about this program, please contact our Medical Education Team at elearning@oncologyeducation.com.

 

 

 

Oncology Clinical News

Bristol-Myers Kidney Cancer Drug Fails Late-stage Trial

(Reuters) Aug 15, 2017 - Bristol-Myers Squibb Co said on Tuesday its combination drug to treat previously untreated patients with advanced or metastatic renal cell carcinoma, a type of kidney cancer, failed to meet one of the main goals of a late-stage trial.
Read full article.

FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma

(Yahoo! Finance) Aug 16, 2017 - Seattle Genetics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) based on data from the phase 3 ALCANZA trial and two phase 2 investigator-sponsored trials of ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL).
Read full article.

Powered by OBR Oncology